GRI Bio (GRI) Amortization of Deferred Charges (2022 - 2026)
GRI Bio (GRI) posted quarterly Amortization of Deferred Charges of $13000.0 for Q1 2026, up 18.18% year-over-year from $11000.0 in Q1 2025, and up 8.33% quarter-over-quarter from $12000.0 in Q4 2025.
GRI Bio (GRI) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
GRI Bio's Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $13000.0 for Q1 2026.
- In Q1 2026, Amortization of Deferred Charges rose 18.18% year-over-year to $13000.0; the TTM figure through Mar 2026 stood at $50000.0 (up 1766.67% YoY), while the FY2025 annual figure was $48000.0, changed N/A from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $13000.0, up from $12000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $1.2 million in Q2 2023, with the low at -$14000.0 in Q2 2024.
- The 5-year median for Amortization of Deferred Charges is $13000.0 (2023), against an average of $111923.1.
- The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges tumbled 101.21% in 2024, then jumped 185.71% in 2025.
- GRI Bio's Amortization of Deferred Charges stood at $182000.0 in 2022, then plunged by 92.31% to $14000.0 in 2023, then slumped by 200.0% to -$14000.0 in 2024, then surged by 185.71% to $12000.0 in 2025, then climbed by 8.33% to $13000.0 in 2026.
- Business Quant data shows GRI's Amortization of Deferred Charges at $13000.0 in Q1 2026, $12000.0 in Q4 2025, and $13000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | GRI Bio | 3.01 Mn | 3.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,000.00 |
| Mar 31, 2026 | 13,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Dec 31, 2025 | 12,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Sep 30, 2025 | 13,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Mar 31, 2024 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Sep 30, 2023 | 13,000.00 |
| Sep 30, 2023 | 13,000.00 |
| Jun 30, 2023 | 1.16 Mn |
| Jun 30, 2023 | 1.16 Mn |